FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, the adapted PASS study on the drug utilisation, the two surveys targeting HCPs or patients, the PASS from registries in order to characterise the foetal anticonvulsant syndrome in children with anti-epileptic drugs in utero exposure, the retrospective observational study on the association between paternal exposure to valproate and the risk of congenital anomalies and neurodevelopmental disorders including autism in offspring and, the observational study to evaluate and identify the best practice for discontinuation and switching of valproate treatment, are not applicable to the injectable formulations.
Danish: Som følge deraf gælder det tilpassede PASS-studie vedrørende lægemiddelanvendelse, de to undersøgelser rettet mod sundhedspersoner og patienter, PASS-studiet fra registre for at karakterisere det føtale antiepileptikasyndrom hos børn ved in utero-eksponering for antiepileptika, det retrospektive observationsstudie vedrørende sammenhængen mellem paternel eksponering for valproat og risikoen for medfødte misdannelser og udviklingsmæssige sygdomme i nervesystemet, herunder autisme hos afkommet, og det observationsstudie, der skal evaluere og identificere bedste praksis vedrørende seponering og skift af valproat-behandling, ikke for de injicérbare formuleringer.
English: The HCP guide should include the recommendation to inform the parents of young girls using valproate about the need to contact their specialist once their daughter has experienced menarche, information on need for switching when pregnancy planning, on the need to go through the risk acknowledgement form and the patient card, at least annually.
Danish: Vejledningen til sundhedspersoner bør omfatte en anbefaling om at informere forældrene til unge piger, der bruger valproat, om behovet for at kontakte deres speciallæge, når datteren har haft sin første menstruation, oplysning om behovet for at skifte behandling ved planlægning af graviditet og om behovet for som minimum én gang om året at gennemgå risikoerklæringsblanketten og patientkortet.
English: • The PRAC also concluded that there was a need to update the educational materials aimed to fully inform patients and healthcare professionals on the risks to the unborn child when exposed in utero to valproate, and to implement some further risk minimisation measures such as a visual reminder on the outer packaging, a patient card and an acknowledgment form to raise awareness about the risks and the need for contraception.
Danish: • PRAC konkluderede også, at der var et behov for at opdatere informationsmaterialet med henblik på at informere patienterne og sundhedspersonerne fuldt ud om risiciene for det ufødte barn ved in utero-eksponering for valproat og for at gennemføre en række yderligere risikominimerende foranstaltninger som f.eks. en visuel påmindelse på yderemballagen, et patientkort og en erklæringsblanket med henblik på at øge bevidstheden om risiciene og nødvendigheden af prævention.
English: Regarding the circulation of the DHPC, all MAHs are encouraged to collaborate in order to prepare and circulate a single DHPC in each Member State and all MAHs marketing products containing valproate and related substances are required to participate in the dissemination of the information, regardless of the route of administration of their medicinal product(s).
Danish: Hvad angår udsendelse af det direkte brev til sundhedspersoner, opfordres alle indehavere af markedsføringstilladelse til at samarbejde om udarbejdelsen og udsendelsen af et enkelt direkte brev i hver medlemsstat, og alle indehavere af markedsføringstilladelse for lægemidler indeholdende valproat og relaterede stoffer skal deltage i udbredelsen af informationen, uanset administrationsvej for deres lægemidler.
English: A post-authorisation safety study (PASS) using data preferably from existing registries should be performed to further characterise the foetal anticonvulsant syndrome in children with valproate in utero exposure as compared to other anti-epileptic drugs.
Danish: Der bør ligeledes gennemføres et sikkerhedsstudie efter tilladelse til markedsføring (PASS) ved hjælp af data fra eksisterende registre for yderligere at karakterisere det føtale antiepileptikasyndrom hos børn ved in utero-eksponering for valproat sammenholdt med behandling med andre antiepileptika.
English: The PRAC requested the conduct of postauthorisation studies.
Danish: PRAC krævede gennemførelse af studier efter markedsføring.
English: The PRAC recommended the improvement of a HCP guide to make sure that valproate prescribers are aware of the risks associated with the use of this product in female children, women of childbearing potential and pregnant women and requested that the patients are also informed about these risks appropriately.
Danish: PRAC anbefalede forbedring af vejledningen til sundhedspersoner for at sikre, at de læger, der ordinerer valproat, er klar over de risici, der er forbundet med brug af dette lægemiddel hos piger, fertile kvinder og gravide kvinder, og opfordrede til, at patienterne også informeres om disse risici på en hensigtsmæssig måde.
English: Indeed, the HCP guide will provide a reminder to the HCP of the conditions that apply for the administration of valproate (e.g. pregnancy prevention plan), the need to discuss the risks with the patient and check her pregnancy status.
Danish: Vejledningen til sundhedspersoner vil faktisk fungere som påmindelse om de betingelser, der gælder for administrationen af valproat (f.eks. graviditetsforebyggelsesprogrammet), behovet for at drøfte risiciene med patienterne og tjekke deres graviditetsstatus.
English: • The PRAC considered the totality of the data submitted for valproate and related substances with regard to the teratogenic and neurodevelopmental risks, the use in clinical practice and the effectiveness of the risk minimisation measures in place.
Danish: • PRAC vurderede alle de oplysninger, der var indsendt vedrørende valproat og relaterede stoffer, med hensyn til de teratogene og neuro-udviklingsmæssige risici, brugen i klinisk praksis og virkningen af de iværksatte risikominimerende foranstaltninger.
English: • The PRAC confirmed the known risk of intra-uterine exposure to valproate and related substances, associated with an increased risk of developmental disorders and congenital anomalies in the offspring.
Danish: • PRAC bekræftede den kendte risiko for intrauterin eksponering for valproat og relaterede stoffer, der er forbundet med en øget risiko for udviklingsmæssige forstyrrelser og medfødte misdannelser hos afkommet.
English: • The PRAC also reviewed the available scientific evidence on the risk of malformations and neurodevelopmental disorders to offspring after paternal exposure, the risk of malformations and neurodevelopmental disorders to the third generation offspring and considered that further research is needed before conclusions can be drawn.
Danish: • PRAC gennemgik også den tilgængelige videnskabelige evidens for risikoen for misdannelser og udviklingsmæssige sygdomme i nervesystemet hos afkommet efter paternel eksponering, risikoen for misdannelser og udviklingsmæssige sygdomme i nervesystemet hos tredjegenerationsafkommet og vurderede, at yderligere forskning er nødvendig, før der kan drages nogen konklusioner.
English: The patient guide should provide comprehensive information on risks to the unborn child due to in utero exposure to valproate and related substances, the details of the pregnancy prevention programme to avoid valproate exposure during pregnancy and the required actions in terms of pregnancy or intention to become pregnant.
Danish: Patientvejledningen bør indeholde omfattende oplysninger om risiciene for det ufødte barn som følge af in utero-eksponering for valproat og relaterede stoffer, om graviditetsforebyggelsesprogrammet for at undgå valproat-eksponering under graviditet og de nødvendige tiltag i forhold til graviditet og planlægning af graviditet.
English: The annual risk acknowledgement form for injectable formulations of valproate and related substances containing products is intended to act as a periodic reminder and acknowledgement of the risks of valproate for women of childbearing potential (WCBP).
Danish: Formålet med den årlige risikoerklæringsblanket for injicérbare formuleringer af lægemidler indeholdende valproat og relaterede stoffer er at fungere som regelmæssig påmindelse og anerkendelse af risiciene ved valproat for fertile kvinder.
English: Since the injectable formulations are indicated for short-term use with a short treatment duration, this annual risk acknowledgement form is not considered relevant therefore not applicable.
Danish: Da de injicérbare formuleringer er indiceret til kortvarig brug, anses denne årlige risikoerklæringsblanket ikke for relevant.
English: In addition, the guide should familiarise the prescribers with key actions to mitigate the risks associated with the use of valproate in exposed girls and women by using the patient guide and the risk acknowledgment form.
Danish: Derudover bør vejledningen gøre ordinerende læger fortrolige med vigtige tiltag for at minimere risiciene ved brug af valproat hos eksponerede piger og kvinder ved hjælp af patientvejledningen og risikoerklæringsblanketten.
English: A survey among HCP to assess their knowledge and behaviour with regard to the new product information restrictions and whether they received the direct healthcare professional communication (DHPC) and educational materials, and another survey among patients to assess the receipt of the educational materials should be performed.
Danish: Der bør gennemføres en undersøgelse blandt sundhedspersoner for at vurdere deres viden og adfærd med hensyn til de nye begrænsninger i produktinformationen og for at vurdere, om de har modtaget det direkte brev til sundhedspersoner og informationsmaterialet, ligesom der bør gennemføres en anden undersøgelse blandt patienterne for at vurdere modtagelsen af informationsmaterialet.
English: Additionally, such patient card is to be attached to the packaging of valproate and related substances containing medicines, and serve as an additional reminder during the dispensing.
Danish: Patientkortet bør være hæftet på pakningen for lægemidler indeholdelse valproat og relaterede stoffer og tjene som yderligere påmindelse ved udlevering.
English: In cases of patients for whom treatment is initiated with IV valproate formulations and then transferred to oral forms of valproate products, the patient card will be disclosed at the time of dispensing the oral valproate-containing products.
Danish: I de tilfælde, hvor patienter starter på intravenøse formuleringer af valproat og så skifter til orale formuleringer, vil patientkortet være vedlagt, når patienterne får udleveret de orale valproatmidler.
English: In view of the above, the PRAC recommended amendments to the product information, in particular to contraindicate its use to women of childbearing potential that do not fulfil the conditions of a pregnancy prevention program, and communication to healthcare professionals through a direct healthcare professional communication (DHPC).
Danish: I lyset af ovenstående anbefalede PRAC ændringer af produktinformationen, navnlig for at kontraindicere brugen af lægemidlet hos fertile kvinder, der ikke opfylder betingelserne i et graviditetsforebyggelsesprogram, samt oplysning herom gennem et direkte brev til sundhedspersoner.
English: Finally, as the patients will be transferred eventually to non-injectable form of valproate, it is considered that the annual review will be carried out as part of RMMs recommended for oral treatment where the annual risk acknowledgment form will then be used.
Danish: Da patienterne på et tidspunkt vil blive skiftet til ikkeinjicérbare formuleringer af valproat, vurderes det, at den årlige gennemgang vil blive gennemført som led i de risikominimerende foranstaltninger for oral behandling, hvor risikoerklæringsblanketten vil blive anvendt.
English: • The PRAC considered that the pregnancy prevention programme should reflect that in the indication epilepsy, if a woman is planning to become pregnant, a specialist experienced in the management of epilepsy, must reassess valproate therapy and consider alternative treatment options.
Danish: • PRAC vurderede, at graviditetsforebyggelsesprogrammet ved indikationen epilepsi bør anbefale, at kvinder, der ønsker at blive gravide, konsulterer en speciallæge med erfaring i behandling af epilepsi, som skal revurdere valproat-behandlingen og overveje alternative behandlingsmuligheder.
English: Therefore the CMDh recommends the variation to the terms of the marketing authorisations for medicinal products containing substances related to valproate.
Danish: CMDh anbefaler derfor ændring af betingelserne for markedsføringstilladelserne for lægemidler, der indeholder stoffer relateret til valproat.
English: In view of the above, the Committee considers that the benefit-risk balance of medicinal products containing substances related to valproate remains favourable subject to the agreed conditions to the marketing authorisations, and taking into account the agreed amendments to the product information and other risk minimisation measures.
Danish: I lyset af ovenstående vurderer udvalget, at benefit/risk-forholdet for lægemidler, der indeholder stoffer, som er relateret til valproat, fortsat er positivt under forudsætning af, at de vedtagne betingelser for markedsføringstilladelserne og de vedtagne ændringer af produktinformationen og øvrige risikominimerende foranstaltninger gennemføres.
English: The CMDh acknowledges correspondence received from a MAH (Laboratoires Aguettant, France) of medicinal products containing valproate injectable (intravenous; IV) formulations, and requesting further clarity for the implementation of the pharmacovigilance activities and risk minimization measures adopted by the PRAC for these IV formulation indicated for the temporary management of epilepsy when administration via oral route is not possible.
Danish: CMDh har modtaget en henvendelse fra en indehaver af markedsføringstilladelse (Laboratoires Aguettant, Frankrig) for lægemidler indeholdende injicérbare (intravenøse) valproat-formuleringer, hvori denne anmoder om yderligere oplysninger om gennemførelsen af de lægemiddelovervågningsaktiviteter og de risikominimerende foranstaltninger, som PRAC har vedtaget for disse intravenøse lægemidler, der er indiceret til midlertidig behandling af epilepsi, når oral administration ikke er mulig.
English: Additionally, as the IV valproate formulations will likely be administered by different HCPs than the usual treating physicians, having a HCP guide in place for these products is crucial and therefore such HCP guide will also be provided to prescribers of IV formulation of valproate containing products.
Danish: Eftersom de intravenøse formuleringer af valproat sandsynligvis vil blive administreret af andre sundhedspersoner end de sædvanlige behandlende læger, er det yderst vigtigt at have en vejledning også for disse lægemidler, og derfor vil en sådan vejledning blive udleveret til de læger, der ordinerer lægemidler indeholdende intravenøse formuleringer af valproat.
English: Further investigation is recommended by PRAC.
Danish: PRAC anbefaler, at der gennemføres yderligere studier.
English: This patient card should be attached at the outer carton to prompt as a reminder the discussion between the pharmacist and the patient at the time of the product dispensing.
Danish: Patientkortet bør hæftes fast på yderemballagen, så det fungerer som en anledning til drøftelse mellem apotekspersonalet og patienten ved udleveringen.
English: The PRAC recommended that the patient guide for female children, adolescents and women who are being prescribed valproate is further developed and improved.
Danish: PRAC anbefalede, at patientvejledningen til piger, unge piger og kvinder, der får ordineret valproat, udvides med flere oplysninger for at gøre den bedre.
English: In particular, experience from HCPs regarding the discontinuation of valproate or switch to other treatment was provided.
Danish: Sundhedspersonerne bidrog især med deres erfaring med seponering af valproat eller skift til anden behandling.
English: Regarding the visual reminder on the outer packaging, it is considered that it is crucial to remind to the HCPs that valproate should not be administered to women of childbearing potential (WCBP) who do not fulfil the pregnancy prevention plan requirements, or to pregnant patients, thus initiating a discussion about the risks of valproate with the patient.
Danish: Hvad angår den visuelle påmindelse på yderemballagen, vurderer udvalget, at det er af afgørende betydning at minde sundhedspersonerne om, at valproat ikke bør anvendes hos fertile kvinder, der ikke opfylder kravene i graviditetsforebyggelsesprogrammet, eller gravide patienter, og at de bør drøfte risiciene ved valproat med patienterne.
English: In order to provide adequate information, it should be tailored for different situations in the life-time of a woman and be age-appropriate: the first prescription, women continuing valproate treatment and not trying to have a child, women of childbearing potential continuing valproate treatment and considering trying to have a child, pregnant women (unplanned pregnancy) whilst continuing valproate treatment.
Danish: Vejledningen bør være udformet, således at den giver kvinderne relevante oplysninger i forhold til det sted, de er i livet, og deres alder: den første recept; kvinder, der fortsætter valproat og ikke ønsker at blive gravide; fertile kvinder, der fortsætter valproat og ønsker at blive gravide, samt kvinder, der er blevet ufrivilligt gravide, mens de fortsætter på valproat-behandling.
English: The Committee, as a consequence, recommends the variation to the terms of the marketing authorisations for medicinal products containing substances related to valproate.
Danish: Udvalget anbefaler som følge heraf, at betingelserne for markedsføringstilladelse ændres for lægemidler indeholdende stoffer, der er relateret til valproat.
English: The CMDh, as a consequence, considers that the benefit-risk balance of medicinal products containing substances related to valproate remains favourable subject to the amendments to the product information and to the conditions described above.
Danish: Som følge af ovennævnte finder CMDh, at benefit/risk-forholdet for lægemidler, der indeholder stoffer relateret til valproat, fortsat er positivt under forudsætning af, at de førnævnte ændringer indføres i produktinformationen og i henhold til ovennævnte betingelser.
English: Choi CS, Gonzales EL, Kim KC, Yang SM, Kim JW, Mabunga DF, et al.
Danish: 2 Choi CS, Gonzales EL, Kim KC, Yang SM, Kim JW, Mabunga DF, et al. The transgenerational inheritance of autism-like phenotypes in mice exposed to valproic acid during pregnancy.
English: The MAH requests CMDh to clarify the implementation of the PRAC outcome for injectable forms by further differentiating the routine/additional risk minimization activities to be considered for the noninjectable products and those also applicable to the injectable products.
Danish: Indehaveren af markedsføringstilladelse anmoder CMDh om at tydeliggøre gennemførelsen af resultatet af PRAC's gennemgang for injicérbare formuleringer ved at foretage en underopdeling mellem de almindelige/yderligere risikominimerende aktiviteter, der vedrører ikke-injicérbare lægemidler, og dem, der vedrører injicérbare lægemidler.
English: Educational measures are necessary in order to ensure that healthcare professionals and patients are informed about the risks associated with valproate in http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Valproate_and_related_substa nces/human_referral_prac_000032.jsp&mid=WC0b01ac05805c516f pregnant women and women of childbearing potential and on the measures necessary to minimise the risk of exposure on valproate in pregnancy.
Danish: Informationstiltag er nødvendige for at sikre, at sundhedspersoner og patienter er klar over risiciene ved valproat hos gravide kvinder og fertile kvinder og de foranstaltninger, der er nødvendige for at minimere risikoen for eksponering for valproat under graviditet.
English: valproate indeed may induce transgenerational alterations of gene expression to the offspring and the types of consequent effects.
Danish: PRAC er også enig i, at det er nødvendigt med yderligere forskning for at undersøge, om valproat faktisk kan inducere transgenerationelle forandringer af genekspressionen i afkommet, og hvilke typer af følgevirkninger der kan forventes.
English: For their use in the treatment of bipolar disorders and prophylaxis of migraine these products are contraindicated in pregnancy.
Danish: Lægemidlerne er kontraindicerede under graviditet til behandling af bipolær sindslidelse og forebyggelse af migræne.
English: This was not shown for teratogenic effects as malformations in the first generation offspring was not observed in the second and third generation offspring (Choi et al, 2016)2.
Danish: førstegenerationsafkommet ikke sås i anden- og tredjegenerationsafkommet (Choi et al, 2016)2 Selvom der er adskillige begrænsninger, tyder studiet på, at der er en vis transgenerationel påvirkning.
English: solvent: 5 ml
Danish: Solvens: 5 ml
English: EU/1/01/177/002 SonoVue
Danish: EU/1/01/177/002 SonoVue 8 µl / ml
English: Powder and solvent for dispersion for injection
Danish: Pulver og solvens til injektionsvæske, dispersion
English: 1 vial + 1 pre-filled syringe + 1 'MiniSpike' rec. device
Danish: 1 hætteglas + 1 fyldt injektionssprøjte +1 særskilt ‘MiniSpike' rekonstitutionsanordning
English: Strength Pharmaceutical Form
Danish: Særnavn Styrke Lægemiddelform Indgivelsesvej Emballage
English: Intravenous use, Intravesical use powder: vial (glass); solvent: pre-filled syringe (glass)
Danish: Pulver: hætteglas Solvens: Fyldt injektionssprøjte (glas)
English: Pack size
Danish: EU Nummer
English: Immediate Packaging
Danish: Indhold Pakningsstørrelse
English: (× 0.85 for female patients)
Danish: (×0,85 for kvinder)
English: in addition to your current treatment.
Danish: sammen med din nuværende behandling.
English: and certain other medicines may influence each other (interaction).
Danish: og anden medicin kan påvirke hinanden (interaktion).
English: is for oral use only.
Danish: er kun til oral anvendelse.
English: either twice or three times a day.
Danish: 2 gange eller 3 gange dagligt.
English: is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.
Danish: er ikke beregnet til at blive brugt alene, men skal altid anvendes i kombination med anden behandling mod epilepsi.
English: hard capsules regularly at the same time each day.
Danish: kapsler regelmæssigt og på samme tid hver dag.
English: Following repeated administration, steady state is achieved within 24 to 48 hours.
Danish: Efter gentagne doser nås steady state inden for 24-48 timer.
English: for you to help treat your epilepsy when your current treatment is not controlling your condition.
Danish: til behandling af din epilepsi, hvis din nuværende behandling ikke kan kontrollere din tilstand.
English: • lorazepam (used for treating anxiety).
Danish: • lorazepam (anvendes til behandling af angst)
English: The effect of pregabalin on newborns/infants is unknown.
Danish: Virkningen af pregabalin på nyfødte/spædbørn er ukendt.
English: These symptoms may occur more commonly or severely if you have been taking pregabalin for a longer period of time.
Danish: Disse symptomer kan forekomme oftere eller i en alvorligere grad, hvis du har taget pregabalin i længere tid.
English: B-dul Theodor Pallady nr.50, sector 3, Bucharest, cod 032266 Romania
Danish: B-dul Theodor Pallady nr.50, sector 3, Bukarest, cod 032266 Rumænien
English: 1.23 × [140 - age (years)] × weight (kg) serum creatinine (µmol/l)
Danish: 1,23 ×[140-alder (år)] × vægt (kg) serumkreatinin (µmol/l)
English: normally except if you have problems with your kidneys.
Danish: som normalt, medmindre du har nyreproblemer.
English: Angioedema, allergic reaction
Danish: Angioødem, allergiske reaktioner